Novartis to Build Radioligand Therapy Facility in Winter Park, Florida
Novartis is expanding its U.S. manufacturing footprint with a new 35,000‑square‑foot radioligand therapy (RLT) facility in Winter Park, Florida. The site is part of the company’s $23 billion investment strategy to advance precision cancer treatments and improve access for patients. RLT combines tumor-targeting molecules with therapeutic radioisotopes to deliver radiation directly to cancer cells, making proximity to treatment centers critical. The Winter Park facility is expected to come online by 2029 and will complement existing sites in Indiana, New Jersey, and California.
The company said the facility underscores Novartis’s commitment to advanced oncology care while leveraging Florida’s growing skilled workforce in life sciences manufacturing. CEO Vas Narasimhan highlighted that this expansion strengthens the RLT supply chain, bringing treatments closer to patients and supporting the broader growth of innovative therapies in the United States.